Carla Miller
Nurse Practitioner · Milford, DENPI 1992137731
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 129 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 24.6% of the total. Reporting peaked in 2021 at $1,233 and has fallen 83.8% since, to $199 in 2025.
Across 129 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$530
- Boehringer Ingelheim$276
- AstraZeneca$214
- Kowa Pharmaceuticals America, Inc.$161
- Astellas Pharma US Inc$161
- Lilly USA, LLC$119
- plus $696 from 17 others
What the payments were for
- Food & beverage$2,158100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $530 |
| Boehringer Ingelheim | 18 | $276 |
| AstraZeneca | 12 | $214 |
| Kowa Pharmaceuticals America, Inc. | 12 | $161 |
| Astellas Pharma US Inc | 9 | $161 |
| Lilly USA, LLC | 6 | $119 |
| Pfizer | 7 | $105 |
| Novo Nordisk | 5 | $100 |
| Merck | 5 | $76 |
| Sunovion Pharmaceuticals Inc. | 3 | $65 |
| Amgen | 3 | $54 |
| Jazz Pharmaceuticals Inc. | 3 | $47 |
| Eisai Inc. | 2 | $37 |
| Exact Sciences | 2 | $36 |
| Johnson & Johnson | 2 | $30 |
| Neos Therapeutics, LP | 2 | $28 |
| Biohaven Pharmaceuticals, Inc. | 1 | $24 |
| GSK | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Vistapharm, Inc. | 1 | $12 |
How this compares
$2,158 in reported general payments places this provider in the 85th percentile of 487 nurse practitioner providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 41 | $59,357 |
| MounjaroTirzepatide | 44 | $57,072 |
| JardianceEmpagliflozin | 22 | $30,626 |
| Gabapentin | 134 | $2,650 |
| Atorvastatin Calcium | 205 | $2,373 |
| Omeprazole | 133 | $2,348 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 22 | $2,186 |
| Levothyroxine Sodium | 200 | $2,047 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 38 | $2,044 |
| Celecoxib | 62 | $1,717 |
| Lidocaine | 13 | $1,531 |
| Rosuvastatin Calcium | 98 | $1,483 |
| Esomeprazole Magnesium | 20 | $1,344 |
| Lisinopril | 157 | $1,204 |
| Fluticasone Propionate | 39 | $1,142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $100 | $59,35741 claims |
| Lilly USA, LLCMounjaro, Olanzapine | $119 | $57,82060 claims |
| Boehringer IngelheimJardiance | $276 | $30,62622 claims |
| AbbVieSynthroid | $530 | $60139 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 487 nurse practitioner providers in Delaware.
Other nurse practitioner in Milford
- Craig LaingMilford$51K
- Marie RenziMilford$3K
- Wendy SurguyMilford$3K
- Meghan McCarterSeaford$170K
- Chandni PatelMiddletown$113K
- Colleen DitroWilmington$16K
- Sedelle Henderson-BamideleNewark$13K
- Jennifer HubbardWilmington$12K
- Kathleen HudsonMillville$10K
- Nancy Townsend O'DayMillsboro$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.